Circulating microRNAs as potential biomarkers to detect transformation of Barrett’s oesophagus to oesophageal adenocarcinoma

Matsuzaki, Juntaro; Suzuki, Hidekazu

doi:10.1136/bmjgast-2017-000160

Cited by 12 publications

(9 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have analyzed the role of circulating miR-143 as a biomarker in malignant diseases. Just recently, it was demonstrated that patients with acute myeloid leukemia and esophageal adenocarcinoma, disease states which are associated with the activation of immune cells, display decreased serum levels of miR-143 [42, 43], which is in line with our results. Moreover, miR-143 might be directly involved in systemic inflammation and defending bacterial infection.…”

Section: Discussionsupporting

confidence: 92%

Serum Levels of miR-143 Predict Survival in Critically Ill Patients

et al. 2019

View full text Add to dashboard Cite

Background and Aims Recent data suggested a potential role of miR-143 as a biomarker for systemic inflammation and infection. However, its role in critical illness and sepsis is only poorly understood. Methods We determined circulating levels of miR-143 in 218 critically ill patients, of which 135 fulfilled sepsis criteria, and compared them to 76 healthy controls. Results were correlated with clinical records. Results In the total cohort of critically ill patients from a medical intensive care unit (ICU), miR-143 serum levels tended to be lower compared to healthy control samples, but this difference did not reach statistical significance. In ICU patients, serum levels of miR-143 were independent of disease etiology, including the presence of sepsis, or severity of disease. Importantly, low miR-143 serum levels were associated with an unfavorable short- and long-term prognosis in ICU patients. Our study identified different optimal cut-off values at which low miR-143 serum levels predicted mortality with a high diagnostic accuracy. In line with this, concentrations of circulating miR-143 correlated with markers of organ failure such as creatinine, bilirubin, or lactate in our cohort of critically ill patients. Conclusion Low miR-143 serum levels are indicative for an unfavorable short- and long-term prognosis in critically ill patients admitted to a medical ICU. Our data suggest a previously unrecognized role for miR-143 measurements as a novel prognostic marker in critically ill patients.

show abstract

Section: Discussionsupporting

confidence: 92%

Serum Levels of miR-143 Predict Survival in Critically Ill Patients

et al. 2019

View full text Add to dashboard Cite

show abstract

“…We [ 36 ] also analyzed tissue and blood miRNAs from human interleukin-1β (IL-1β) transgenic mice (L2-IL-1β mice) as a model of BE. We then compared expression of human plasma miRNAs in eight EAC patients, eight BE patients, and six healthy individuals using a public dataset.…”

Section: Resultsmentioning

confidence: 99%

Extracellular miRNAs for the Management of Barrett’s Esophagus and Esophageal Adenocarcinoma: A Systematic Review

Inokuchi

Ochiya

Matsuzaki

2020

JCM

Self Cite

View full text Add to dashboard Cite

Esophageal adenocarcinoma (EAC), the major histologic type of esophageal cancer (EC) in Western countries, is a disease with a poor prognosis, primarily due to usual diagnosis at an advanced stage. The prevalence of EAC has increased in recent years, both in Western countries and in Asia. Barrett’s esophagus (BE) is a precursor lesion of EAC. Therefore, early detection and proper management of BE and EAC is important to improve prognosis. Here, we systematically summarize current knowledge about the potential utility of extracellular microRNAs (miRNAs), which are thought to be non-invasive biomarkers for many diseases, for these purposes. A search of the PubMed and Embase databases identified 22 papers about extracellular miRNAs that have potential utility for management of EAC. Among them, 19 were EAC-related and ten were BE-related; some of these dealt with both conditions. The articles included studies reporting diagnosis, prognosis, and treatment responses. Multiple papers report dysregulation of miR-194-5p in BE and miR-21-5p, -25-3p, and -93-5p in EAC. Although it will take time to utilize these miRNAs in clinical practice, they are likely to be useful non-invasive markers in the future.

show abstract

“…Furthermore, it was revealed that miR-141 was involved in the pathogenesis of ulcerative colitis by targeting C-X-C motif chemokine ligand 5 (11). Emerging evidence has previously identified miRs that can be secreted from cells into the extracellular environment, where they are stable and resistant to degradation by RNases (12,13). Circulating miRs are therefore desirable candidates as both endocrine signaling molecules and disease markers (12,13).…”

Section: Introductionmentioning

confidence: 99%

Peripheral blood miR‑372 as a biomarker for ulcerative colitis via direct targeting of NLRP12

Shen

2019

Exp Ther Med

View full text Add to dashboard Cite

The present study aimed to investigate the expression pattern and underlying mechanism of microRNA-372 (miR-372) in the progression of ulcerative colitis (UC). Reverse transcription-quantitative polymerase chain reaction was used to measure miR-372 expression levels in the blood and colonic mucosa tissue samples from patients with UC. The present study demonstrated that levels of miR-372 were significantly increased in the blood and colonic mucosa tissue samples from patients with UC compared with healthy controls. Furthermore, the level of serum miR-372 was positively correlated with the level of serum c-reactive protein. Receiver operating characteristic analysis indicated that levels of miR-372 detected in serum and tissue samples could be used to screen for patients with UC from healthy controls. These results indicated a potential role of miR-372 as a diagnostic marker and therapeutic target for patients with UC. Furthermore, a conserved miR-372 binding site in the 3'untranslated region of the NLR family pyrin domain containing 12 (NLRP12) was identified. Dual luciferase assay demonstrated that overexpression of miR-372 significantly reduced the relative luciferase activity of pmirGLO-NLRP12-3'UTR compared with control pmirGLO. In addition, western blot analysis indicated that overexpression of miR-372 significantly decreased the protein expression level of NLRP12. Therefore it was hypothesized that miR-372 may promote the progression of UC by suppressing NLRP12 protein expression and thereby inducing the excessive production of inflammatory cytokines. In conclusion, high levels of miR-372 detected in peripheral blood samples may serve a role as a potential biomarker to screen potential patients with UC from healthy controls.

show abstract

Circulating microRNAs as potential biomarkers to detect transformation of Barrett’s oesophagus to oesophageal adenocarcinoma

Cited by 12 publications

References 62 publications

Serum Levels of miR-143 Predict Survival in Critically Ill Patients

Serum Levels of miR-143 Predict Survival in Critically Ill Patients

Extracellular miRNAs for the Management of Barrett’s Esophagus and Esophageal Adenocarcinoma: A Systematic Review

Peripheral blood miR‑372 as a biomarker for ulcerative colitis via direct targeting of NLRP12

Contact Info

Product

Resources

About